SCYL3 Inhibitors
SCYL3 inhibitors are a collection of chemical entities that attenuate the functional activity of SCYL3 by modulating the signaling pathways and cellular processes it is involved in. Rapamycin, for instance, by inhibiting the mTOR pathway, constricts the cellular environment conducive to SCYL3's role in regulating protein synthesis and cell growth, thereby indirectly limiting its activity. Wortmannin and LY 294002, as PI3K inhibitors, disrupt the PI3K-Akt signaling cascade, pivotal for SCYL3's involvement in intracellular trafficking, leading to a consequential diminution of its functional activity. Staurosporine, a broad-spectrum kinase inhibitor, potentially affects kinases that modulate SCYL3 function and localization, further reducing its activity within the cell. Dasatinib and Erlotinib, through their targeted inhibition of Src family kinases and EGFR respectively, diminish phosphorylation events and growth factor signaling that are likely to regulate SCYL3's functional dynamics.
Continuing this theme, Lapatinib's inhibition of EGFR and HER2/neu, along with Sorafenib's multi-kinase inhibition, which includes VEGFR, PDGFR, and Raf kinases, further contribute to the network of reduced signaling pathways that SCYL3 may depend on. Sunitinib's impediment of receptor tyrosine kinases also suppresses the growth factor signaling that influences SCYL3's role in cellular processes. Moreover, U0126, SB 203580, and SP600125 target the MAPK signaling pathways, with U0126 and SB 203580 specifically inhibiting the MEK and p38 MAPK pathways, respectively, and SP600125 obstructing the JNK pathway. These inhibitors weaken the signaling that could affect SCYL3's function, thereby indirectly diminishing its activity. Collectively, these chemical compounds exert a compounding inhibitory effect on SCYL3 by hampering the signaling pathways that are essential for its normal function within cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that can lead to the inhibition of downstream signaling required for protein synthesis and cell growth. By inhibiting mTOR, which is essential for cell cycle progression, Rapamycin indirectly diminishes the functional activity of SCYL3 by restricting the cellular environment in which SCYL3 typically operates. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor which impairs the PI3K-Akt signaling pathway. Since SCYL3 has been implicated in intracellular trafficking that is responsive to growth factor signals, Wortmannin's action would lead to an indirect reduction of SCYL3's functional role by curtailing the signaling required for its trafficking function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY2 94002 is another PI3K inhibitor, similar to Wortmannin, that also leads to the downregulation of the PI3K-Akt pathway. This would indirectly decrease SCYL3 activity by reducing the signaling that modulates intracellular trafficking where SCYL3 is active. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent protein kinase inhibitor that can affect multiple kinases within cellular signaling pathways. This broad action includes potential indirect effects on the kinases that modify SCYL3 function and localization, thus diminishing its activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor that could decrease the phosphorylation of substrates involved in growth factor signaling pathways. Since SCYL3 is part of the cellular mechanisms responding to these signals, its activity is likely diminished by Dasatinib's kinase inhibition. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an EGFR inhibitor that blocks the epidermal growth factor receptor signaling pathway, which could play a role in the intracellular trafficking processes involving SCYL3. Inhibition of EGFR could lead to decreased functional activity of SCYL3 due to lower signaling through this pathway. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that blocks the function of both EGFR and HER2/neu. This would indirectly inhibit SCYL3 by reducing the growth factor signaling that may regulate SCYL3's role in intracellular trafficking. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that targets multiple receptors, including VEGFR, PDGFR, and Raf kinases. By inhibiting these kinases, Sorafenib would diminish SCYL3 activity by reducing the signaling that SCYL3 relies on for its functional role in cellular processes. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor, affecting signaling pathways such as PDGFR and VEGFR. This results in an indirect diminishment of SCYL3's functional activity by lowering the growth factor signaling that regulates SCYL3's role in cellular processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an MEK inhibitor that indirectly reduces ERK pathway signaling. Given the ERK pathway's role in various cellular processes, its inhibition by U0126 could indirectly lead to the diminished functional activity of SCYL3 by affecting the pathways that modulate SCYL3's role. | ||||||